{"originalText": "，患者5月余前（2013年6月）于我院肛肠外科确诊直肠癌伴肝转移，，肝脏增强MR示：肝脏内可见多发大小不一的类圆形长T1长T2信号影，最大者位于肝右外叶，呈不规则团块状，大小4.47×3.13CM,增强扫描病灶边缘明显不均匀强化，中心强化不明显。于我院肛肠外科行FOLFOX新辅助化疗2周期。复查全腹CT提示肝脏多发占位缩小，最大者位于肝右外叶，大小2.8×2.1CM，3月余前（2013年8月8日）于我院肛肠外科行直肠癌低位前切除术，术后恢复良好，，术后病理回报：进展期直肠癌，溃疡浸润型，中分化腺癌，II级，断端无癌，，浸润深度:透浆膜，脉管癌栓（+），肌间神经节侵犯（+），结外肿瘤种植（+），淋巴结可见癌转移（3/12枚），DUKES，分期：C2期,（，病理号：508）。患者术后拒绝行基因检测及应用靶向药物，继续FOLFOX辅助化疗2周期。2013年10月28日复查全腹CT提示肝脏多发占位，较大者位于右外叶，大小约4.0*2.8CM,提示疾病进展，后转入我科，行FOLFOX辅助化疗1周期。下周期化疗后出现肝功异常，口服两环醇进行保肝降酶治疗。末次化疗距今3周，现为求进一步治疗收入我科，饮食睡眠可，精神体力可，小便正常，大便日一次略干燥，近来体重未见明显减轻。ECOG，评分：1分。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 25, "end_pos": 32}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 34, "end_pos": 36}, {"label_type": "影像检查", "overlap": 0, "start_pos": 36, "end_pos": 40}, {"end_pos": 44, "label_type": "解剖部位", "overlap": 0, "start_pos": 42}, {"end_pos": 76, "label_type": "解剖部位", "overlap": 0, "start_pos": 72}, {"label_type": "影像检查", "overlap": 0, "start_pos": 148, "end_pos": 152}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 154, "end_pos": 156}, {"end_pos": 172, "label_type": "解剖部位", "overlap": 0, "start_pos": 168}, {"end_pos": 217, "label_type": "手术", "overlap": 0, "start_pos": 208}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 233, "end_pos": 255}, {"label_type": "影像检查", "overlap": 0, "start_pos": 388, "end_pos": 392}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 394, "end_pos": 396}, {"end_pos": 469, "label_type": "药物", "overlap": 0, "start_pos": 466}, {"end_pos": 473, "label_type": "解剖部位", "overlap": 0, "start_pos": 472}]}
